ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2070

Myeloid-Derived Suppressor Cells Accumulated in Spleens of Mice with Collagen-Induced Arthritis and Inhibited Immune Response of CD4+ T Cells

Wataru Fujii1, Eishi Ashihara2, Hideyo Hirai3, Hidetake Nagahara1, Kazuki Fujioka1, Ken Murakami1, Kaoru Nakamura1, Takahiro Seno1, Aihiro Yamamoto1, Hidetaka Ishino1, Masataka Kohno1, Taira Maekawa3 and Yutaka Kawahito1, 1Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 2Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Kyoto, Japan, 3Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: T cells

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis: Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Myeloid-derived suppressor cells (MDSCs), firstly reported in patients with cancer, have a myeloid origin and an ability to suppress T cell responses. MDSCs are characterized by the co-expression of the myeloid-cell lineage differentiation antigens Gr1 and CD11b. Many investigators have demonstrated that MDSCs promote tumor progression via T cell tolerance in patients with cancers and tumor-bearing mice. However, as for autoimmune diseases, the roles of MDSCs in autoimmune disease remain controversial. Here we investigate the roles of MDSCs in autoimmune arthritis using collagen-induced arthritis (CIA) models.

Methods: CIA was induced in 7-8week-old DBA/1 mice by intradermal injection of 200 μg of bovine type II collagen (CII) in Freund’s complete adjuvant on day 0, followed by a booster injection of 200 μg of CII in Freund’s incomplete adjuvant on day 21. The severity of arthritis in each paw was evaluated 3 times weekly. We first analyzed the number of Gr1+ /CD11b+ MDSCs in the spleens of mice with CIA by flow cytometry at the onset, the peak, and the convalescence of CIA. Next, MDSCs were isolated from spleens of mice with CIA by magnetic cell separation. Carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled CD4+ T cells were stimulated with anti-CD3/CD28 antibodies (Abs) and cultured in the presence of 30 U/ml interleukin (IL)-2 with or without MDSCs for 5 days. We investigated CD4+ T cell proliferation using flow cytometric measurement of CFSE dye dilution. Next, MDSCs were co-cultured with CD4+ T cells stimulated with anti-CD3/CD28 Abs for 3 days. We measured cytokines released into supernatant using specific enzyme-linked immunosorbent assay (ELISA).

Results: In a murine arthritis model, MDSCs significantly accumulated in the spleens of mice with CIA at the peak of its severity. MDSCs inhibited the proliferation of CD4+ T cells in response to anti-CD3/CD28 Abs in vitro. When we co-cultured CD4+ T cells and MDSCs interferon (IFN)-γ and IL-6 released into supernatant were significantly decreased, 97.6 ± 16.1 pg/ml to 79.8 ± 10.1 pg/ml (p < 0.05), 10.4 ± 2.1 pg/ml to 2.9 ± 1.0 pg/ml (p < 0.01), respectively.

Conclusion: MDSCs accumulated in the spleens of mice with CIA. These MDSCs inhibited CD4+ T cell proliferation and pro-inflammatory cytokine production in vitro. These findings may indicate the protective roles of MDSCs against autoimmune arthritis�, which could be exploited for new cell-based therapies. We are now investigating the function of MDSCs in vivo.


Disclosure:

W. Fujii,
None;

E. Ashihara,
None;

H. Hirai,
None;

H. Nagahara,
None;

K. Fujioka,
None;

K. Murakami,
None;

K. Nakamura,
None;

T. Seno,
None;

A. Yamamoto,
None;

H. Ishino,
None;

M. Kohno,
None;

T. Maekawa,
None;

Y. Kawahito,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/myeloid-derived-suppressor-cells-accumulated-in-spleens-of-mice-with-collagen-induced-arthritis-and-inhibited-immune-response-of-cd4-t-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology